Human papillomavirus polypeptides and immunogenic compositions
The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides for fusions of HPV E6 and E7 in which the E6 and/or E7 contains one or more mutations. These mutations abrogate the transformation activity of these oncogenic proteins and, thus, confer safety to the E6/E7 fusions. In addition, these fusions maintain or increase the immunogenic efficacy of E6 and E7. Any gene or protein delivery method can be used to deliver or package the immunogenic compositions of the present invention.
1. An isolated nucleic acid encoding a polypeptide comprising human papillomavirus E6 and E7 polypeptides, wherein the E7 polypeptide has mutations at any one or more of the amino acids conesponding to amino acids 24, 26 or 91 of SEQ ID NO: 14 and the E6 polypeptide has no mutations or has mutations at any one or more of the amino acids corresponding to amino acids 63 or 106 of SEQ ID NO: 13.
2. The nucleic acid of claim 1 wherein the nucleotide sequence of E7 precedes the nucleotide sequence of E6.
3. An expression vector comprising the nucleic acid sequence of claim 1 under the control of an expression control sequence.
4. A host cell comprising the nucleic acid of claim 1 .
5. A host cell which expresses a polypeptide comprising human papillomavirus E6 and E7 polypeptides, wherein the E7 polypeptide has mutations at any one or more of the amino acids corresponding to amino acids 24, 26 or 91 of SEQ ID NO: 14 and the E6 polypeptide has no mutations or has mutations at any one or more of the amino acids corresponding to amino acids 63 or 106 of SEQ ID NO: 13.
6. A host cell comprising the expression vector of claim 3 .
7. An immunogenic composition comprising the nucleic acid of claim 1 .
8. A method of preventing cervical cancer, which method comprises administering to an individual the expression vector of claim 3 in an amount sufficient to produce a protective immune response.
9. A method of treating cervical cancer, which method comprises administering to a patient diagnosed with cervical cancer the expression vector of claim 3 in an amount sufficient to produce a protective immune response.